Loading
Life sciences · Journal article
The Oncologist · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background and objective Approximately one third of men with metastatic prostate cancer die from causes other than prostate cancer. Little is known about the long-term outcomes of men with metastatic prostate cancer, in particular those who do not develop androgen pathway resistance. The objective of this study is to describe those with long term survival and disease response to initial therapy and their clinical outcomes. Methods This is a single institution, retrospective study of patients with metastatic hormone sensitive prostate cancer diagnosed prior to 1/1/2019 and alive as of 12/31/2024. Clinical and demographic features are described at baseline and follow up, with outcomes after treatment cessation. Key Findings and limitations 145 patients were included with a median age at diagnosis of 61 years. 51 patients (35.2%) had metastatic disease at diagnosis and 108 (74.5%) had bone metastases at the time of metastatic disease. The median follow-up from the date of metastatic disease was 8.4 years. 89 (61.4%) patients continued to have disease response to initial therapy after a median of 8.8 years. 32 patients stopped therapy, and of those, 25 recovered testosterone, with 11 patients continuing to have an undetectable prostate specific antigen (PSA) (8% of total cohort and 34% of those who stopped therapy). Conclusions and clinical implications In this cohort, most patients did not have further progression of disease, and 8% of patients had durable treatment-free remissions. Further research is needed on treatment cessation in men with exceptional responses to ADT.